-DOCSTART- -X- O
Influenza -X- _ B-Patient
represents -X- _ O
a -X- _ O
substantial -X- _ O
global -X- _ O
healthcare -X- _ O
burden -X- _ O
, -X- _ O
with -X- _ O
annual -X- _ O
epidemics -X- _ O
resulting -X- _ O
in -X- _ O
3– -X- _ O
5 -X- _ O
million -X- _ O
cases -X- _ O
of -X- _ O
severe -X- _ O
illness -X- _ O
with -X- _ O
a -X- _ O
significant -X- _ O
associated -X- _ O
mortality. -X- _ O
In -X- _ O
addition -X- _ O
, -X- _ O
the -X- _ O
risk -X- _ O
of -X- _ O
a -X- _ O
virulent -X- _ O
and -X- _ O
lethal -X- _ O
influenza -X- _ O
pandemic -X- _ O
has -X- _ O
generated -X- _ O
widespread -X- _ O
and -X- _ O
warranted -X- _ O
concern. -X- _ O
Currently -X- _ O
licensed -X- _ O
influenza -X- _ O
vaccines -X- _ O
are -X- _ O
limited -X- _ O
in -X- _ O
their -X- _ O
ability -X- _ O
to -X- _ O
induce -X- _ O
efficacious -X- _ O
and -X- _ O
long- -X- _ O
lasting -X- _ O
herd -X- _ O
immunity. -X- _ O
In -X- _ O
addition -X- _ O
, -X- _ O
and -X- _ O
as -X- _ O
evidenced -X- _ O
by -X- _ O
the -X- _ O
H1N1 -X- _ B-Patient
pandemic -X- _ O
in -X- _ O
2009 -X- _ O
, -X- _ O
there -X- _ O
can -X- _ O
be -X- _ O
a -X- _ O
significant -X- _ O
delay -X- _ O
between -X- _ O
the -X- _ O
emergence -X- _ O
of -X- _ O
a -X- _ O
pandemic -X- _ O
influenza -X- _ O
and -X- _ O
an -X- _ O
effective -X- _ O
, -X- _ O
antibody- -X- _ O
inducing -X- _ O
vaccine. -X- _ O
There -X- _ O
is -X- _ O
, -X- _ O
therefore -X- _ O
, -X- _ O
a -X- _ O
continued -X- _ O
need -X- _ O
for -X- _ O
new -X- _ O
, -X- _ O
efficacious -X- _ O
vaccines -X- _ O
conferring -X- _ O
cross-clade -X- _ O
protection—obviating -X- _ O
the -X- _ O
need -X- _ O
for -X- _ O
biannual -X- _ O
reformulation -X- _ O
of -X- _ O
seasonal -X- _ O
influenza -X- _ O
vaccines. -X- _ O
Development -X- _ O
of -X- _ O
such -X- _ O
a -X- _ O
vaccine -X- _ O
would -X- _ O
yield -X- _ O
enormous -X- _ O
health -X- _ O
benefits -X- _ O
to -X- _ O
society -X- _ O
and -X- _ O
also -X- _ O
greatly -X- _ O
reduce -X- _ O
the -X- _ O
associated -X- _ O
global -X- _ O
healthcare -X- _ O
burden. -X- _ O
There -X- _ O
are -X- _ O
a -X- _ O
number -X- _ O
of -X- _ O
alternative -X- _ O
influenza -X- _ O
vaccine -X- _ O
technologies -X- _ O
being -X- _ O
assessed -X- _ O
both -X- _ O
preclinically -X- _ O
and -X- _ O
clinically. -X- _ O
In -X- _ O
this -X- _ O
review -X- _ O
we -X- _ O
discuss -X- _ O
viral -X- _ B-Intervention
vectored -X- _ I-Intervention
vaccines -X- _ I-Intervention
, -X- _ I-Intervention
either -X- _ I-Intervention
recombinant -X- _ I-Intervention
live-attenuated -X- _ I-Intervention
or -X- _ I-Intervention
replication-deficient -X- _ I-Intervention
viruses -X- _ I-Intervention
, -X- _ O
which -X- _ O
are -X- _ O
current -X- _ O
lead -X- _ O
candidates -X- _ O
for -X- _ O
inducing -X- _ O
efficacious -X- _ O
and -X- _ O
long-lasting -X- _ O
immunity -X- _ O
toward -X- _ O
influenza -X- _ O
viruses. -X- _ O
These -X- _ O
alternate -X- _ O
influenza -X- _ O
vaccines -X- _ O
offer -X- _ O
real -X- _ B-Outcome
promise -X- _ I-Outcome
to -X- _ I-Outcome
deliver -X- _ I-Outcome
viable -X- _ I-Outcome
alternatives -X- _ I-Outcome
to -X- _ I-Outcome
currently -X- _ I-Outcome
deployed -X- _ I-Outcome
vaccines -X- _ I-Outcome
and -X- _ I-Outcome
more -X- _ I-Outcome
importantly -X- _ I-Outcome
may -X- _ I-Outcome
confer -X- _ I-Outcome
long-lasting -X- _ I-Outcome
and -X- _ I-Outcome
universal -X- _ I-Outcome
protection -X- _ I-Outcome
against -X- _ I-Outcome
influenza -X- _ I-Outcome
viral -X- _ I-Outcome
infection -X- _ I-Outcome
. -X- _ O

